You are viewing an expired study
This study is not currently recruiting Study Participants on If you would like to find active studies please search for clinical trials

Wichita, Kansas

  • Schizoaffective Disorder


The purpose of this study is to investigate a safe treatment interruption interval(s) for re-initiation of bifeprunox at a therapeutic dose. The study duration is approximately 7 to 10 weeks.


Inclusion Criteria: - Diagnosis of Schizophrenia or Schizoaffective disorder - 18-55 years Exclusion Criteria: - Subjects who are acutely psychotic - Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia - Subjects at significant risk of suicide - Subjects with a seizure disorder



Primary Contact:

Study Director
Global Clinical Director Solvay
Solvay Pharmaceuticals

Backup Contact:


Location Contact:

Wichita, Kansas
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.